Home Cart Sign in  
Chemical Structure| 2055362-74-6 Chemical Structure| 2055362-74-6

Structure of ADH-503
CAS No.: 2055362-74-6

Chemical Structure| 2055362-74-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.

Synonyms: (Z)-Leukadherin-1 choline; GB1275

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ADH-503

CAS No. :2055362-74-6
Formula : C27H28N2O5S2
M.W : 524.65
SMILES Code : C[N+](C)(C)CCO.O=C([O-])C1=CC=C(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)C=C1
Synonyms :
(Z)-Leukadherin-1 choline; GB1275
MDL No. :N/A
InChI Key :GOWDQYRMBCOOJR-JHMJKTBASA-M
Pubchem ID :145711124

Safety of ADH-503

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ADH-503

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MIAPaCa-2 cells 20 μM 7 days Combining ADH-503 with immunotherapy (αPD-1) and chemotherapy (gemcitabine/paclitaxel) significantly reduced tumor cell viability, proliferation, metabolic activity, immunomodulation, and secretion of immunosuppressive and tumor growth-promoting cytokines Adv Healthc Mater. 2023 Jun;12(14):e2201907
BxPC-3 cells 20 μM 7 days Combining ADH-503 with immunotherapy (αPD-1) and chemotherapy (gemcitabine/paclitaxel) significantly reduced tumor cell viability, proliferation, metabolic activity, immunomodulation, and secretion of immunosuppressive and tumor growth-promoting cytokines Adv Healthc Mater. 2023 Jun;12(14):e2201907
human microglia-like cells (MGLs) 10 μM 1 day ADH-503 restored phagocytosis in KO MGLs Stem Cell Reports. 2024 Aug 13;19(8):1074-1091

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Orthotopic KP2 and KI PDAC models Oral gavage 30, 60, or 120 mg/kg Twice a day (BID) for 8-14 days ADH-503 reduced the numbers of tumor-infiltrating CD11b+ cells, including monocytes, granulocytes, and macrophages, and enhanced dendritic cell responses, thereby improving anti-tumor T cell immunity. Sci Transl Med. 2019 Jul 3;11(499):eaau9240
Mice MeCP2 knockout mouse model Oral gavage 120 mg/kg Daily administration until the end of the experiment ADH-503 significantly improved disease progression and increased survival Stem Cell Reports. 2024 Aug 13;19(8):1074-1091

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.53mL

1.91mL

0.95mL

19.06mL

3.81mL

1.91mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories